Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzoic Acid Hydrazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | MPO | P05164 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM5A | P29375 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20078583 | 0.97 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL4515671 | 0.97 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL83514 | 0.97 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL6469726 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL31087636 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL29125493 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL1128823 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL922906 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL31491462 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL29999087 | 0.95 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285773-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8609881-B2 | Cure accelerators for anaerobic curable compositions | Henkel IP US LCC (US) | 2013-12-17 | — | — | US | disclosed |
| US-8106141-B2 | Cure accelerators for anaerobic curable compositions | HENKEL CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2285771-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel Corporation (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009137448-A2 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281335-A1 | Cure Accelerators for Anaerobic Curable Compositions | HENKEL CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090277356-A1 | Cure Accelerators for Anaerobic Curable Compositions | ACLY, ACAD9, CCNY | CYP3A4 2198/4885MPO 402/4885GAA 851/4885 |
| US-20090281335-A1 | Cure Accelerators for Anaerobic Curable Compositions | CAT, MRM1, ACLY | CYP3A4 2057/4885MPO 236/4885GAA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.